Actively Recruiting
Plasmodium Immunotherapy for Breast and Liver Cancers
Led by CAS Lamvac Biotech Co., Ltd. · Updated on 2024-02-20
60
Participants Needed
1
Research Sites
411 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to evaluate the safety and preliminarily evaluate the effectiveness of Plasmodium immunotherapy for advanced breast cancers and advanced liver cancers.The treatment will last 4-6 weeks from the day of successful infection and will be terminated by antimalarial drugs.
CONDITIONS
Official Title
Plasmodium Immunotherapy for Breast and Liver Cancers
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 18 and 70 years, any gender
- Confirmed advanced breast cancer or advanced liver cancer by histopathology and imaging with clear, measurable tumor lesions
- Previously received at least one standard cancer therapy
- Completed chemotherapy or radiotherapy at least 1 month ago, or completed targeted drug therapy at least 5 half-lives ago
- ECOG performance status of 0 or 1
- Expected survival of 6 months or longer
- Platelet count 100 10^9/L, neutrophils 1.5 10^9/L, hemoglobin 100 g/L without significant red blood cell abnormalities or certain anemias
- Immune cell counts and immune function close to normal
- Heart, lung, liver, and kidney functions basically normal (Child-Pugh liver class A or B, creatinine 1.5 times upper limit of normal)
- Patient able to comply with follow-up
- Able to understand and sign informed consent
You will not qualify if you...
- Severe hemoglobin disease or severe G6PD deficiency
- History of splenectomy or enlarged spleen
- Drug addiction or alcohol dependence
- Serious or uncontrolled systemic diseases including active infections, grade 3 hypertension, unstable angina, heart failure class III or IV, severe arrhythmia, liver or kidney dysfunction, metabolic diseases, neurological or psychiatric disorders
- Receiving other anti-tumor treatments concurrently
- Significantly reduced immune function compared to normal population
- Severely impaired lung function (MNW <39%), unable to get out of bed, or shortness of breath at rest
- Advanced liver cancer with severe esophageal varices
- Persistent cough, difficulty breathing, poor appetite, or inability to cooperate
- Poor physical condition making immune therapy intolerable as assessed by researchers
- Pregnant or breastfeeding women
- Women of childbearing age with positive pregnancy test
- Any other condition deemed unsuitable by the researchers for study participation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Plasmodiun vivax
Guangzhou, Guangdong, China, 510000
Actively Recruiting
Research Team
Q
Qin Li, M.D
CONTACT
Z
Zhang Su Yi, M.D
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here